# US 2026/0216278 A1 · Vancomycin pharmaceutical composition and kit thereof, and method for treating bacterial infection by using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216278 A1
- Document ID: US20260216278A1
- Status: Published application
- Kind: A1
- Application number: 19/454,470
- Filed: 2026-01-21
- Published: 2026-07-30
- Earliest claimed: 2025-01-24
- Assignees: Salus Therapeutics, Inc.
- Applicants: Salus Therapeutics Inc.
- Inventors: Yong QIU; Yu-Cheng Tseng; Chia-Chian Hung; Yu-Yang Chiang
- Web page: https://patentgrep.com/patent/US20260216278A1

## CPC

- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a vancomycin pharmaceutical composition, comprising a liposomal vancomycin, wherein the liposomal vancomycin comprises vancomycin or a pharmaceutical acceptable salt thereof, and a first liposome comprising sphingomyelin and cholesterol. Also provided is a kit of the vancomycin pharmaceutical composition and method for treating bacterial infection by using the vancomycin pharmaceutical composition or the kit of the vancomycin pharmaceutical composition.

## Claims

### Claim 1

A vancomycin pharmaceutical composition, comprising a liposomal vancomycin, wherein the liposomal vancomycin comprises a therapeutically effective amount of vancomycin or a pharmaceutical acceptable salt thereof, and a first liposome comprising sphingomyelin and cholesterol.

### Claim 2 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, wherein, the weight ratio of the vancomycin to the first liposome is from about 9:1 to about 0.06:1.

### Claim 3 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, wherein the first liposome comprises 40 wt % to 60 wt % of cholesterol and 60 wt % to 40 wt % of sphingomyelin.

### Claim 4 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, wherein the liposomal vancomycin has a Z-average size of 60 nm to 180 nm.

### Claim 5 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, further comprising a second liposome, wherein the second liposome comprises sphingomyelin.

### Claim 6 (depends on 5)

The vancomycin pharmaceutical composition as claimed in claim 5, wherein the second liposome further comprises a lipid selected from cholesterol, phospholipids, phospholipid derivatives, or a combination thereof.

### Claim 7 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, wherein the vancomycin pharmaceutical composition has an encapsulating efficiency of 3% to 25%.

### Claim 8 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, wherein the vancomycin pharmaceutical composition has a pH value of 3.0 to 7.0.

### Claim 9 (depends on 1)

The vancomycin pharmaceutical composition as claimed in claim 1, which is administered through injection or inhalation.

### Claim 10

A kit of a vancomycin pharmaceutical composition, comprising:
(a) a liposomal vancomycin, comprising a therapeutically effective amount of vancomycin or a pharmaceutical acceptable salt thereof, and a first liposome comprising sphingomyelin and cholesterol; and
(b) a second liposome, comprising sphingomyelin;
wherein (a) the liposomal vancomycin and (b) the second liposome are separately stored.

### Claim 11 (depends on 10)

The kit as claimed in claim 10, wherein the first liposome further comprises a pharmaceutically acceptable excipient.

### Claim 12 (depends on 10)

The kit as claimed in claim 10, wherein, in the liposomal vancomycin, the weight ratio of the vancomycin to the first liposome is from about 9:1 to about 0.06:1.

### Claim 13 (depends on 10)

The kit as claimed in claim 10, wherein the first liposome comprises 40 wt % to 60 wt % of cholesterol and 60 wt % to 40 wt % of sphingomyelin.

### Claim 14 (depends on 10)

The kit as claimed in claim 10, wherein the liposomal vancomycin in a liquid suspension form has a Z-average size from 60 nm to 180 nm.

### Claim 15 (depends on 10)

The kit as claimed in claim 10, wherein the liposomal vancomycin has an encapsulating efficiency of 3% to 25% after reconstitution with the second liposome in a liquid suspension form or a reconstitution liquid selected from water and an intravenous fluid.

### Claim 16 (depends on 10)

The kit as claimed in claim 10, wherein the second liposome further comprises a lipid selected from cholesterol, phospholipids, phospholipid derivatives, or a combination thereof.

### Claim 17 (depends on 10)

The kit as claimed in claim 10, wherein the liposomal vancomycin is in a lyophilized solid form, and the second liposome is in a lyophilized solid form or a liquid suspension form.

### Claim 18 (depends on 10)

The kit as claimed in claim 10, further comprising one or more portions of (c) a reconstitution liquid selected from water or an intravenous fluid.

### Claim 19 (depends on 10)

The kit as claimed in claim 10, wherein the liposomal vancomycin in a lyophilized solid form is reconstituted with the second liposome in a liquid suspension form or a reconstitution liquid selected from water and an intravenous fluid, to obtain a liposomal vancomycin in a liquid suspension form; when the second liposome in a liquid suspension form is used to reconstitute the liposomal vancomycin in a lyophilized solid form, the second liposome in the kit is in a liquid suspension form.

### Claim 20 (depends on 1)

A method for treating bacterial infection, comprising: administering the vancomycin pharmaceutical composition as claimed in claim 1 to a subject in need thereof.

### Claim 21 (depends on 10)

A method for treating bacterial infection, comprising: providing the kit as claimed in claim 10; reconstituting the liposomal vancomycin with the second liposome to obtain a vancomycin pharmaceutical composition; and administering the vancomycin pharmaceutical composition to a subject in need thereof.

### Claim 22 (depends on 10)

A method for treating bacterial infection, comprising: providing the kit as claimed in claim 10; reconstituting the liposomal vancomycin with a reconstitution liquid selected from water and an intravenous fluid to obtain a reconstituted liposomal vancomycin; and administering the reconstituted liposomal vancomycin and the second liposome to a subject in need thereof separately or simultaneously.
